Literature DB >> 9050944

Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay.

C A Benedict1, A J MacKrell, W F Anderson.   

Abstract

A single chain antibody (scFv) was constructed from a hybridoma expressing the anti-CD34 monoclonal antibody My10. The scFv was expressed in the mouse fibroblast cell line NIH 3T3, and purified from culture supernatant via an epitope tag fused to the C-terminus of the protein. The scFv equilibrium dissociation constant (KD) was determined to be 2.4 X 10(-7) M using a fluorescence based flow cytometry assay involving recognition of the epitope tag, and bound approximately 24-fold less avidly to CD34 expressing KG-1a cells than the native antibody My10. This novel and previously unreported method for determining antibody binding affinity offers several advantages over alternative methods. It is rapid and simple, and unlike methods that directly label the antibody, it involves no covalent modifications of antibody variable domain residues that could potentially interfere with antigen binding. The KD for the anti-CD33 antibody HuG1 (Caron et al. (1992) The biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 52, 6761-6767) was determined as well. The close agreement of this value and the previously reported value, determined by a radioligand competition method, validates the use of this assay for antibody affinity determination. We discuss various potential applications for this anti-CD34 scFv.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050944     DOI: 10.1016/s0022-1759(96)00227-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  31 in total

1.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.

Authors:  Meike Hutt; Aline Färber-Schwarz; Felix Unverdorben; Fabian Richter; Roland E Kontermann
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

3.  Functional activity of CD40 antibodies correlates to the position of binding relative to CD154.

Authors:  T A Barr; A W Heath
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

4.  A differential cell capture assay for evaluating antibody interactions with cell surface targets.

Authors:  David J Sherman; Vania E Kenanova; Eric J Lepin; Katelyn E McCabe; Ken-Ichiro Kamei; Minori Ohashi; Shutao Wang; Hsian-Rong Tseng; Anna M Wu; Christian P Behrenbruch
Journal:  Anal Biochem       Date:  2010-02-21       Impact factor: 3.365

5.  Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Authors:  Yu Zhou; Daryl C Drummond; Hao Zou; Mark E Hayes; Gregory P Adams; Dmitri B Kirpotin; James D Marks
Journal:  J Mol Biol       Date:  2007-05-10       Impact factor: 5.469

6.  Discovery of internalizing antibodies to basal breast cancer cells.

Authors:  Yu Zhou; Hao Zou; Christina Yau; Lequn Zhao; Steven C Hall; Daryl C Drummond; Shauna Farr-Jones; John W Park; Christopher C Benz; James D Marks
Journal:  Protein Eng Des Sel       Date:  2018-01-01       Impact factor: 1.650

7.  A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.

Authors:  E Faitschuk; V Nagy; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2016-06-14       Impact factor: 5.250

8.  Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.

Authors:  Roland Stork; Emmanuelle Campigna; Bruno Robert; Dafne Müller; Roland E Kontermann
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

9.  A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.

Authors:  Jinxu Fang; Liang Xiao; Kye-Il Joo; Yarong Liu; Chupei Zhang; Shuanglong Liu; Peter S Conti; Zibo Li; Pin Wang
Journal:  Int J Cancer       Date:  2015-09-14       Impact factor: 7.396

10.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Authors:  Bin Liu; Fraser Conrad; Audrey Roth; Daryl C Drummond; Jeff P Simko; James D Marks
Journal:  J Mol Med (Berl)       Date:  2007-06-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.